Mucosolvan Perlonguets (Ambroxol Hydrochloride)

Ambroxol Hydrochloride, the active ingredient in Mucosolvan Perlonguets, is a mucolytic agent presented as an oral formulation for oral use. It helps to thin and loosen thick bronchial secretions, facilitating expectoration in patients with respiratory conditions that produce viscous sputum.

GNH USA supplies Mucosolvan Perlonguets as a licensed, GDP‑compliant international pharmaceutical supplier serving hospitals, pharmacies and clinics worldwide.

Mucosolvan Perlonguets, containing ambroxol hydrochloride, is used in the management of respiratory disorders characterized by excessive or thick mucus production.

- Acute bronchitis with productive cough: improves clearance of sputum and reduces cough duration. - Chronic obstructive pulmonary disease (COPD) with mucus hypersecretion: aids in reducing sputum viscosity and facilitates expectoration. - Other respiratory conditions with thick, viscous sputum: enhances mucociliary clearance and eases breathing.

Ambroxol may be associated with a range of adverse reactions, which are generally classified by frequency and severity.

Common Side Effects: - Altered taste sensation: transient metallic or bitter taste. - Nausea: mild to moderate discomfort in the stomach. - Diarrhoea: loose stools occurring shortly after administration. - Stomach discomfort: abdominal pain or dyspepsia. - Skin rash: mild erythematous eruption. - Headache: occasional mild headache.

Serious or Rare Side Effects: - Allergic reactions: urticaria, pruritus, or angioedema. - Severe skin reactions: Stevens‑Johnson syndrome or toxic epidermal necrolysis. - Hepatic enzyme elevation: potential liver function abnormalities. - Eosinophilia: increased eosinophil count in blood. - Anaphylaxis: rare but life‑threatening hypersensitivity. - Respiratory distress: bronchospasm in susceptible individuals.

When prescribing or dispensing Mucosolvan Perlonguets, consider the following precautions.

- Renal impairment: use with caution in patients with severe kidney disease. - Hepatic disease: monitor liver function in patients with pre‑existing liver conditions. - Asthma: may provoke bronchospasm; observe closely in asthmatic patients. - Pregnancy and lactation: safety not established; evaluate risk‑benefit before use. - Drug interactions: review concomitant medications for potential interactions. - Store at ambient temperature: keep below 25 °C, protect from moisture and light in the original container.

Ambroxol can interact with several medicines; awareness of the interaction level helps guide clinical decisions.

Major Interactions (Avoid): - Anticholinergic agents: may diminish mucolytic efficacy. - Cytotoxic chemotherapy: increased risk of pulmonary toxicity. - Beta‑agonist bronchodilators: potential additive bronchospasm.

Moderate Interactions (Monitor Closely): - Macrolide antibiotics: may raise ambroxol plasma concentrations. - Warfarin: monitor INR as ambroxol can affect coagulation parameters. - Theophylline: observe for altered respiratory response or side‑effect profile.